protocol_number,criterion_type,criterion_text,category,is_required,sort_order,parsed_json,created_at,updated_at
AR882-301,exclusion,"2. History of symptomatic kidney stones within the past 6 months, nephrectomy, and/or renal transplant.",medical,f,0,"{""field"": ""condition"", ""value"": ""kidney stones"", ""operator"": ""equals""}",2025-04-01 19:30:18.678807,2025-07-22 19:16:44.201729
AR882-301,exclusion,5. Hemoglobin < 10 g/dL (males) or < 9 g/dL (females) at Screening.,laboratory,f,0,"{""test"": ""hemoglobin"", ""field"": ""lab_value"", ""value"": 10, ""operator"": ""greater_than""}",2025-04-01 19:30:57.96791,2025-07-22 19:16:47.975766
AR882-301,inclusion,1. Male or female participants ≥ 18 to ≤ 85 years of age at the time of signing the informed consent form (ICF).,demographic,t,0,"{""unit"": ""years"", ""field"": ""age"", ""value"": [18, 85], ""operator"": ""between""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.871317
AR882-301,inclusion,"2. Participants that have documented medical records stating history of gout. If no documented medical history of gout, delegated site personnel should complete the American College Rheumatology/ European Alliance of Associations for
   Rheumatology gout classification criteria calculator to confirm gout diagnosis.",medical,t,0,"{""field"": ""diagnosis"", ""value"": ""gout"", ""operator"": ""equals""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:24.580448
AR882-301,inclusion,3. Must have had an occurrence of ≥ 2 self-reported gout flares in the last 12 months.,medical,t,0,"{""field"": ""condition_count"", ""value"": 2, ""operator"": ""greater_than_or_equal"", ""condition"": ""gout flares""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:27.008769
AR882-301,inclusion,4. Body weight must be ≥ 50 kg and body mass index between ≥ 18 to ≤ 45 kg/m2.,biometric,t,0,"{""field"": ""bmi"", ""value"": 18.5, ""operator"": ""greater_than_or_equal""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:28.672301
AR882-301,inclusion,5. Male or female participants. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.,other,f,0,"{""text"": ""5. Male or female participants. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.146201
AR882-301,inclusion,"6. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.",other,f,0,"{""text"": ""6. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:20.920015
AR882-301,inclusion,7. Participants must meet one of the following criteria: a. ULT-naïve participants OR b. Participants entering the study on ULT are willing to washout for a minimum of 10 days before the first IP administration on Day 1.,other,t,0,"{""text"": ""7. Participants must meet one of the following criteria: a. ULT-naïve participants OR b. Participants entering the study on ULT are willing to washout for a minimum of 10 days before the first IP administration on Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:37.177695
AR882-301,inclusion,"8. Participant meets one of the following criteria at Screening: a. If not currently taking an approved ULT, participant must have an sUA value ≥ 7.0 mg/dL (416 µmol/L) OR b. If entering the study on ULT treatment, participant must 
  have an sUA value > 6.0 mg/dL (357 µmol/L).",other,f,0,"{""text"": ""8. Participant meets one of the following criteria at Screening: a. If not currently taking an approved ULT, participant must have an sUA value ≥ 7.0 mg/dL (416 µmol/L) OR b. If entering the study on ULT treatment, participant must \n  have an sUA value > 6.0 mg/dL (357 µmol/L)."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.41381
AR882-301,inclusion,9. Serum creatinine must be < 3.0 mg/dL and estimated CLcr ≥ 30 mL/min by Cockcroft-Gault formula.,other,f,0,"{""text"": ""9. Serum creatinine must be < 3.0 mg/dL and estimated CLcr ≥ 30 mL/min by Cockcroft-Gault formula."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.35879
AR882-301,inclusion,10. Participants taking concomitant medications must be on a stable dose from 4 weeks before Day 1 and agree to maintain the stable dose through to the Final Follow-Up Visit.,other,f,0,"{""text"": ""10. Participants taking concomitant medications must be on a stable dose from 4 weeks before Day 1 and agree to maintain the stable dose through to the Final Follow-Up Visit."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.079283
AR882-301,inclusion,11. Participants previously prescribed pegloticase or rasburicase must have stopped taking these medications for at least 90 days before Day 1.,other,f,0,"{""text"": ""11. Participants previously prescribed pegloticase or rasburicase must have stopped taking these medications for at least 90 days before Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.488142
AR882-301,inclusion,12. Must be free of any clinically significant disease that would interfere with study evaluations or procedures as per the Investigator's judgment.,other,f,0,"{""text"": ""12. Must be free of any clinically significant disease that would interfere with study evaluations or procedures as per the Investigator's judgment."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.802947
AR882-301,exclusion,1. A history of clinically significant disorders or presenting with signs or symptoms of clinically significant disorders that are not well-controlled as per the Investigator's judgment.,other,f,0,"{""text"": ""1. A history of clinically significant disorders or presenting with signs or symptoms of clinically significant disorders that are not well-controlled as per the Investigator's judgment."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:16:55.258747
AR882-301,exclusion,3. History of xanthinuria.,other,f,0,"{""text"": ""3. History of xanthinuria."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:16:58.626327
AR882-301,exclusion,4. History of tumor lysis syndrome or Lesch-Nyhan syndrome.,other,f,0,"{""text"": ""4. History of tumor lysis syndrome or Lesch-Nyhan syndrome."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:16:57.778302
AR882-301,exclusion,"6. Alanine aminotransferase or aspartate aminotransferase > 2.0 × ULN, total bilirubin > 3 mg/dL, and/or international normalized ratio > 1.7 (not on anti-coagulant therapy) at Screening.",other,f,0,"{""text"": ""6. Alanine aminotransferase or aspartate aminotransferase > 2.0 × ULN, total bilirubin > 3 mg/dL, and/or international normalized ratio > 1.7 (not on anti-coagulant therapy) at Screening."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:16:59.62731
AR882-301,exclusion,"7. Participants that have moderately impaired hepatic function (Child-Pugh Class B) or advanced hepatic dysfunction (Child-Pugh Class C), or participants that are recipients of a liver transplant.",other,f,0,"{""text"": ""7. Participants that have moderately impaired hepatic function (Child-Pugh Class B) or advanced hepatic dysfunction (Child-Pugh Class C), or participants that are recipients of a liver transplant."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:02.272186
AR882-301,exclusion,8. Positive serology to human immunodeficiency virus ([HIV]; HIV1 and HIV2) with a confirmatory positive HIV assay and/or hepatitis C virus (HCV) antibodies with a confirmatory positive HCV RNA and/or hepatitis B surface antigen.,other,f,0,"{""text"": ""8. Positive serology to human immunodeficiency virus ([HIV]; HIV1 and HIV2) with a confirmatory positive HIV assay and/or hepatitis C virus (HCV) antibodies with a confirmatory positive HCV RNA and/or hepatitis B surface antigen."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:02.949986
AR882-301,exclusion,"9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin that has been successfully treated. Participants with a history of other malignancies that have been treated with curative intent at least 3 years 
  before Screening with no recurrence may also be eligible if approved by the Sponsor Medical Monitor (or designee).",other,f,0,"{""text"": ""9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin that has been successfully treated. Participants with a history of other malignancies that have been treated with curative intent at least 3 years \n  before Screening with no recurrence may also be eligible if approved by the Sponsor Medical Monitor (or designee)."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:06.367464
AR882-301,exclusion,"10. History of complete heart block, QTc prolongation, Torsades de pointes, or any family history of congenital QT interval prolongation syndrome.",other,f,0,"{""text"": ""10. History of complete heart block, QTc prolongation, Torsades de pointes, or any family history of congenital QT interval prolongation syndrome."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:08.030449
AR882-301,exclusion,"11. History within 6 months before Screening and/or presence of substance use disorders including alcohol use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition.",medical,f,0,"{""text"": ""11. History within 6 months before Screening and/or presence of substance use disorders including alcohol use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:11.370161
AR882-301,exclusion,"12. History of severe allergic reaction (e.g., anaphylaxis) to a food, drug, chemical, or natural substance.",other,t,0,"{""text"": ""12. History of severe allergic reaction (e.g., anaphylaxis) to a food, drug, chemical, or natural substance."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:56.824987
AR882-301,exclusion,"13. Uncontrolled hypertension (e.g., systolic pressure > 160 mm Hg, or diastolic pressure > 95 mm Hg on repeated measures).",other,f,0,"{""field"": ""diagnosis"", ""value"": ""hypertension""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:13.813089
AR882-301,exclusion,14. QT corrected for heart rate according to Fridericia (QTcF) interval > 450 msec (males) or > 480 msec (females) at Screening.,other,f,0,"{""text"": ""14. QT corrected for heart rate according to Fridericia (QTcF) interval > 450 msec (males) or > 480 msec (females) at Screening."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:15.885729
AR882-301,exclusion,15. Any use of concomitant medications that have a moderate or high risk of prolonging the QT/QTc interval within 14 days before Day 1.,other,f,0,"{""text"": ""15. Any use of concomitant medications that have a moderate or high risk of prolonging the QT/QTc interval within 14 days before Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.001419
AR882-301,exclusion,16. Participants requiring long-term use of high-dose salicylates (> 1g/day) will be excluded.,other,f,0,"{""text"": ""16. Participants requiring long-term use of high-dose salicylates (> 1g/day) will be excluded."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.931647
AR882-301,exclusion,17. Participants requiring or taking warfarin will be excluded.,other,f,0,"{""text"": ""17. Participants requiring or taking warfarin will be excluded."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.868446
AR882-301,exclusion,18. Received any vaccinations (including coronavirus disease-2019 and influenza) within 14 days before dosing on Day 1.,other,f,0,"{""text"": ""18. Received any vaccinations (including coronavirus disease-2019 and influenza) within 14 days before dosing on Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.067268
AR882-301,exclusion,19. Received pegloticase or rasburicase within the 3 months before Screening.,other,f,0,"{""text"": ""19. Received pegloticase or rasburicase within the 3 months before Screening."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.348426
AR882-301,exclusion,"20. Previously dosed with AR882 or previously received an IP, investigational biological agent, or investigational device within 3 months or 5 half-lives of the IP, whichever is longer.",demographic,f,0,"{""text"": ""20. Previously dosed with AR882 or previously received an IP, investigational biological agent, or investigational device within 3 months or 5 half-lives of the IP, whichever is longer."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.720971
AR882-301,exclusion,21. Safety laboratory abnormality values considered clinically significant by the Investigator.,laboratory,f,0,"{""text"": ""21. Safety laboratory abnormality values considered clinically significant by the Investigator."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.137779
AR882-301,exclusion,"22. Positive test for drugs of abuse (cocaine, methamphetamine, amphetamine, benzodiazepines, methadone, barbiturates, or opiates) at Screening. Participants with positive test(s) for amphetamines, barbiturates, benzodiazepines, or 
  opiates who present documentation of a valid prescription for the respective drug will be permitted if the prescription is deemed acceptable by the Investigator.",laboratory,f,0,"{""text"": ""22. Positive test for drugs of abuse (cocaine, methamphetamine, amphetamine, benzodiazepines, methadone, barbiturates, or opiates) at Screening. Participants with positive test(s) for amphetamines, barbiturates, benzodiazepines, or \n  opiates who present documentation of a valid prescription for the respective drug will be permitted if the prescription is deemed acceptable by the Investigator."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.216474
AR882-301,exclusion,23. Inadequate venous access or unsuitable veins for repeated venipuncture in the opinion of the Investigator.,other,f,0,"{""text"": ""23. Inadequate venous access or unsuitable veins for repeated venipuncture in the opinion of the Investigator."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.280374
AR882-301,exclusion,24. Any acute illness within 1 week of Day 1 or active infection within 2 weeks of Day 1.,other,f,0,"{""text"": ""24. Any acute illness within 1 week of Day 1 or active infection within 2 weeks of Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.436126
AR882-301,exclusion,25. Had major surgery within 3 months of Day 1.,other,f,0,"{""text"": ""25. Had major surgery within 3 months of Day 1."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.290993
AR882-301,exclusion,"26. Donated whole blood within 8 weeks before Day 1 or donated plasma within 4 weeks before Screening. Participants must agree to refrain from donation of blood, fluids, and other tissue throughout the treatment period until 12 weeks
   after receiving the last dose of IP.",other,f,0,"{""text"": ""26. Donated whole blood within 8 weeks before Day 1 or donated plasma within 4 weeks before Screening. Participants must agree to refrain from donation of blood, fluids, and other tissue throughout the treatment period until 12 weeks\n   after receiving the last dose of IP."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.787814
AR882-301,exclusion,27. Clinically relevant intolerance or allergy to AR882 or is known or suspected to have hypersensitivity to benzbromarone and/or any ingredient in the study treatments.,other,f,0,"{""text"": ""27. Clinically relevant intolerance or allergy to AR882 or is known or suspected to have hypersensitivity to benzbromarone and/or any ingredient in the study treatments."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:21.661797
AR882-301,exclusion,"28. Is in a situation or with a condition that, in the opinion of the Investigator, may interfere with optimal participation in the study.",other,f,0,"{""text"": ""28. Is in a situation or with a condition that, in the opinion of the Investigator, may interfere with optimal participation in the study."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.577275
AR882-301,exclusion,29. Is involved in other clinical studies throughout the period of this study.,other,f,0,"{""text"": ""29. Is involved in other clinical studies throughout the period of this study."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.508036
AR882-301,exclusion,30. Is unable or unwilling to comply with study restrictions.,other,f,0,"{""text"": ""30. Is unable or unwilling to comply with study restrictions."", ""field"": ""unparsed""}",2025-04-01 19:33:02.324312,2025-07-22 19:17:22.655299
BXP-301,inclusion,"Subjects must: 1. Be willing and able to provide voluntary written informed consent and written authorization for use and disclosure of protected health information. • In the case of pediatric subjects, a parent or legally authorized representative (LAR) must provide written informed consent and sign the health information disclosure form. The child’s assent should also be obtained as required by the overseeing Institutional Review Board (IRB).",laboratory,f,0,,2025-07-25 16:21:05.142681,2025-07-28 19:38:47.735609
BXP-301,inclusion,"2. Be able and willing to fully comply with study procedures and restrictions. • For pediatric subjects, this requirement applies to the parent or LAR.",study_procedures,f,0,,2025-07-25 16:21:05.192329,2025-07-28 19:38:48.020665
BXP-301,inclusion,"3. If a woman of childbearing potential (WOCBP), have a negative urine pregnancy test (UPT) at Visit 1 and be willing to use approved contraception for the duration of the study. If a sexually active adult male with a female partner of childbearing potential, be willing to use approved contraception for the duration of the study. • Non-childbearing potential is defined as a female who is either premenarchal, postmenopausal (no menstrual periods for at least 12 consecutive months without another medical cause), or has undergone documented permanent sterilization, such as a bilateral oophorectomy, hysterectomy, or tubal ligation. • Approved forms of contraception include hormonal (i.e., oral, transdermal, implant, or injection); barrier (i.e., condom or diaphragm with spermicide); intrauterine device; vasectomized partner (6 months minimum); and abstinence.",demographics,f,0,,2025-07-25 16:21:05.229567,2025-07-28 19:38:47.879142
BXP-301,inclusion,"4. At Visit 1, have a clinical diagnosis of suspected bacterial conjunctivitis in at least 1 eye, confirmed by the presence of the following minimal clinical signs and symptoms in that same eye: a. Clinical observation or solicited subject report of purulent or mucopurulent ocular discharge b. Grade ≥ 1 on the modified VBR conjunctival redness scale",laboratory,f,0,,2025-07-25 16:21:05.270849,2025-07-28 19:38:47.805461
BXP-301,inclusion,"5. Have received no ocular treatment for conjunctivitis, aside from eyelid hygiene, ≤14 days prior to Visit 1.",disease_specific,t,0,,2025-07-25 16:21:05.30943,2025-07-28 19:39:02.02258
BXP-301,inclusion,"6. Have a negative viral conjunctivitis (e.g., QuickVue® Adenoviral Conjunctivitis Test) test in both eyes ≤24 hours prior to Visit 1 or at Visit 1.",disease_specific,f,0,,2025-07-25 16:21:05.351141,2025-07-28 19:38:47.947424
BXP-301,inclusion,7. Be willing to discontinue use of cosmetics on the eyelids and eyelashes for the duration of the study.,study_procedures,f,0,,2025-07-25 16:21:05.396645,2025-07-28 19:38:48.105005
BXP-301,inclusion,8. Be willing to discontinue use of contact lenses for the duration of the study.,study_procedures,f,0,,2025-07-25 16:21:05.443852,2025-07-28 19:38:48.24668
BXP-301,exclusion,Subjects must not: 1. Be currently pregnant or lactating (WOCBP).,reproductive,f,0,,2025-07-25 16:21:05.480703,2025-07-28 19:38:47.595176
BXP-301,exclusion,2. Have participated in another clinical trial ≤30 days prior to Visit 1.,medical_history,f,0,,2025-07-25 16:21:05.519072,2025-07-28 19:38:48.179072
BXP-301,exclusion,3. Have received another experimental drug ≤90 days prior to Visit 1.,medical_history,f,0,,2025-07-25 16:21:05.566629,2025-07-28 19:38:48.600869
BXP-301,exclusion,4. Have a household member enrolled in this study.,study_procedures,f,0,,2025-07-25 16:21:05.607297,2025-07-28 19:38:48.31738
BXP-301,exclusion,"5. Have any known history of immunodeficiency disorder or known active conditions predisposing to immunodeficiency, such as human immunodeficiency virus, hepatitis B or C, evidence of active hepatitis A (anti-hepatitis A virus immunoglobulin M), or organ or bone marrow transplant.",disease_specific,t,0,,2025-07-25 16:21:05.658129,2025-07-28 19:39:32.697004
BXP-301,exclusion,6. Be blind or have monocular vision.,general,f,0,,2025-07-25 16:21:05.697996,2025-07-28 19:38:48.385461
BXP-301,exclusion,"7. Have a current or recurrent ocular or systemic disease that could affect study conduct, clinical or laboratory assessments, or the action, absorption, or disposition of the investigational product (IP), per the Investigator’s discretion.",laboratory,f,0,,2025-07-25 16:21:05.739294,2025-07-28 19:38:48.531215
BXP-301,exclusion,8. Have experienced signs and symptoms of bacterial conjunctivitis for >48 hours prior to Visit 1.,laboratory,t,0,,2025-07-25 16:21:05.777203,2025-07-28 19:39:38.123478
BXP-301,exclusion,9. Have a known hypersensitivity to or intolerance of benzalkonium chloride or other components of Fucithalmic or placebo.,general,f,0,,2025-07-25 16:21:05.814336,2025-07-28 19:38:48.807013
BXP-301,exclusion,"10. Have had a diagnosis of or clinical presentation consistent with non-infectious conjunctivitis or non-bacterial ocular infection (e.g., viral, fungal, acanthamoeba, or other parasitic) ≤30 days prior to Visit 1. • History of presumed seasonal or perennial allergic conjunctivitis signs/symptoms is not exclusionary.",laboratory,f,0,,2025-07-25 16:21:05.852794,2025-07-28 19:38:49.109074
BXP-301,exclusion,"11. Have and/or report any of the following at Visit 1: a. Trauma to the eye <3 months prior to Visit 1 or any history of ocular trauma that may affect study outcomes, in the opinion of the Investigator b. Photophobia in conjunction with severe ocular pain c. Blurred vision not cleared by rapid blinking d. Tender eye upon palpation e. Unequal and/or poorly reacting pupil, in the opinion of the Investigator f. White opacity on the cornea",medical_history,f,0,,2025-07-25 16:21:05.891348,2025-07-28 19:38:49.034711
BXP-301,exclusion,12. Have nasolacrimal duct obstruction or punctal plugs at Visit 1.,study_procedures,f,0,,2025-07-25 16:21:05.931972,2025-07-28 19:38:48.736914
BXP-301,exclusion,13. Have had ocular surgical intervention ≤6 months prior to Visit 1 or plans for such intervention during the study period.,medical_history,f,0,,2025-07-25 16:21:05.968736,2025-07-28 19:38:48.882868
BXP-301,exclusion,"14. Have a history of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome.",disease_specific,f,0,,2025-07-25 16:21:06.005552,2025-07-28 19:38:48.955366
BXP-301,exclusion,15. Have an active case or a history of ocular herpes.,medical_history,f,0,,2025-07-25 16:21:06.045494,2025-07-28 19:38:49.246174
BXP-301,exclusion,"16. Have used any of the following treatments within the specified timeframe. Use during the study is also prohibited. a. Cyclosporine eye drops ≤7 days prior to Visit 1 b. Ocular, periocular, or systemic antibiotics ≤14 days prior to Visit 1. At Visit 1, systemic antibiotic use may be permitted if deemed by the Investigator to be clinically necessary to treat a sexually transmitted disease. c. Ocular, periocular, or systemic corticosteroids ≤14 days prior to Visit 1. Stable use (initiated ≥30 days prior to Visit 1) of inhaled and nasal corticosteroids is allowed, given no anticipated change in dose for the duration of the study. Topical dermal steroids are allowed except in the periocular area. d. Topical or systemic non-steroidal immunosuppressive agents ≤14 days prior to Visit 1 e. Topical ocular non-steroidal anti-inflammatory drugs (NSAIDs) ≤14 days prior to Visit 1 f. Topical ophthalmic products, including tear substitutes and over-the-counter (OTC) preparations such as eyelid scrubs, ≤2 hours prior to Visit 1",demographics,f,0,,2025-07-25 16:21:06.083782,2025-07-28 19:38:49.176353
BXP-301,exclusion,17. Be an employee of or immediate family member of an employee (directly related to study conduct) at the investigational site.,study_procedures,f,0,,2025-07-25 16:21:06.123617,2025-07-28 19:38:49.388908
BXP-301,exclusion,"18. Be unsuited for participation in the study for any other reason, per the Investigator’s discretion.",study_procedures,f,0,,2025-07-25 16:21:06.159572,2025-07-28 19:38:49.317376
BXP-301,exclusion,"19. Have recent history (≤6 months) of blepharitis defined by symptoms of routine sticky, crusty or red eyes upon waking.",laboratory,f,0,,2025-07-25 16:21:06.198406,2025-07-28 19:38:49.461279
C3671058,inclusion,Male and female participants ≥50 years of age at the time of consent.,demographic,t,0,"{""text"": ""Male and female participants ≥50 years of age at the time of consent."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:26.170235
C3671058,inclusion,"Participants who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living (ADLs).",other,f,0,"{""text"": ""Participants who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living (ADLs)."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:11:59.365007
C3671058,inclusion,"Participants who are willing and able to comply with scheduled visits, laboratory tests, lifestyle considerations, and other study procedures, including daily completion of the e-diary for 7 days after each study vaccination.",laboratory,f,0,"{""text"": ""Participants who are willing and able to comply with scheduled visits, laboratory tests, lifestyle considerations, and other study procedures, including daily completion of the e-diary for 7 days after each study vaccination."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:00.18981
C3671058,inclusion,"Participants who are determined by medical history, physical examination (if required), and clinical judgement of the investigator to be eligible for inclusion in the study.",other,f,0,"{""text"": ""Participants who are determined by medical history, physical examination (if required), and clinical judgement of the investigator to be eligible for inclusion in the study."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:03.178751
C3671058,inclusion,"Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.",other,f,0,"{""text"": ""Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:04.367552
C3671058,exclusion,Current clinically suspected or polymerase chain reaction (PCR)–confirmed ongoing episode of HZ and/or history of clinically suspected or PCR-confirmed HZ within the past 12 months.,other,t,0,"{""text"": ""Current clinically suspected or polymerase chain reaction (PCR)–confirmed ongoing episode of HZ and/or history of clinically suspected or PCR-confirmed HZ within the past 12 months."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:10.984483
C3671058,exclusion,"History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine.",other,t,0,"{""text"": ""History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:10.984483
C3671058,exclusion,Prior history of any subtype of Guillain Barré syndrome of any etiology.,other,f,0,"{""text"": ""Prior history of any subtype of Guillain Barré syndrome of any etiology."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:10.870189
C3671058,exclusion,"Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator’s opinion, excludes the participant from participating in the study.",demographic,f,0,"{""text"": ""Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator’s opinion, excludes the participant from participating in the study."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:11.938941
C3671058,exclusion,"Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.",laboratory,f,0,"{""text"": ""Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:15.188955
C3671058,exclusion,Current use of any prohibited concomitant medication(s) or those unwilling/unable to use a permitted concomitant medication(s).,other,f,0,"{""text"": ""Current use of any prohibited concomitant medication(s) or those unwilling/unable to use a permitted concomitant medication(s)."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-07-25 16:12:19.820228
C3671058,exclusion,"Previous vaccination with any licensed or investigational RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation.",other,t,0,"{""text"": ""Previous vaccination with any licensed or investigational RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:10.984483
C3671058,exclusion,"Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine during study participation.",other,t,0,"{""text"": ""Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine during study participation."", ""field"": ""unparsed""}",2025-04-05 14:41:19.664537,2025-04-11 13:31:10.984483
CIN-102-123,inclusion,Is a male or female ≥18 years of age,demographic,t,0,"{""text"": ""Is a male or female ≥18 years of age"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:36:06.082661
CIN-102-123,inclusion,"Has a diagnosis of Type 1 or Type 2 diabetes, according to the American Diabetes Association criteria",medical,t,0,"{""field"": ""diagnosis"", ""value"": ""diabetes""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:45.23562
CIN-102-123,inclusion,Has a current diagnosis of diabetic gastroparesis defined by persistent gastrointestinal symptoms consistent with gastroparesis and documented delayed gastric emptying,medical,f,0,"{""text"": ""Has a current diagnosis of diabetic gastroparesis defined by persistent gastrointestinal symptoms consistent with gastroparesis and documented delayed gastric emptying"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:35.533055
CIN-102-123,inclusion,"Has a body mass index between 18 and 49 kg/m2, inclusive, at Screening",other,t,0,"{""text"": ""Has a body mass index between 18 and 49 kg/m2, inclusive, at Screening"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:50.18307
CIN-102-123,inclusion,"Has an HbA1c level ≤10% at Screening and, in the opinion of the Investigator, has stable, well-controlled blood glucose",other,f,0,"{""text"": ""Has an HbA1c level ≤10% at Screening and, in the opinion of the Investigator, has stable, well-controlled blood glucose"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-04-11 13:31:31.327
CIN-102-123,inclusion,"If receiving treatment with GLP-1RA, must meet specific criteria regarding the use and tolerance of GLP-1RA",other,f,0,"{""text"": ""If receiving treatment with GLP-1RA, must meet specific criteria regarding the use and tolerance of GLP-1RA"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.652486
CIN-102-123,inclusion,"Male subjects with female partners of childbearing potential must agree to use 2 medically accepted, effective methods of birth control from Day 1 until 90 days following the final dose of study drug",other,f,0,"{""text"": ""Male subjects with female partners of childbearing potential must agree to use 2 medically accepted, effective methods of birth control from Day 1 until 90 days following the final dose of study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:35.856684
CIN-102-123,inclusion,Male subjects must agree to abstain from sperm donation from Day 1 until 90 days following the final dose of study drug,other,f,0,"{""text"": ""Male subjects must agree to abstain from sperm donation from Day 1 until 90 days following the final dose of study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.073778
CIN-102-123,inclusion,"Female subjects with male partners must be surgically sterile, postmenopausal, or agree to use 2 medically accepted, effective methods of birth control from Day -14 until 60 days following the final dose of study drug",other,f,0,"{""text"": ""Female subjects with male partners must be surgically sterile, postmenopausal, or agree to use 2 medically accepted, effective methods of birth control from Day -14 until 60 days following the final dose of study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:35.929972
CIN-102-123,inclusion,Is willing and able to refrain from pramlintide from Screening until End of Treatment (EOT),other,f,0,"{""text"": ""Is willing and able to refrain from pramlintide from Screening until End of Treatment (EOT)"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.212675
CIN-102-123,inclusion,"Can understand and comply with all study visits, procedures, restrictions, discontinuation of medications, and provide written informed consent",other,f,0,"{""text"": ""Can understand and comply with all study visits, procedures, restrictions, discontinuation of medications, and provide written informed consent"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:35.999498
CIN-102-123,exclusion,Has a known primary cause of gastroparesis other than diabetes,other,f,0,"{""field"": ""diagnosis"", ""value"": ""diabetes""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.146186
CIN-102-123,exclusion,Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesis and/or diabetic ketoacidosis and/or malnutrition,other,f,0,"{""text"": ""Has been hospitalized within 3 months prior to Visit 1 for diabetic gastroparesis and/or diabetic ketoacidosis and/or malnutrition"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.279517
CIN-102-123,exclusion,"Has a history of, or current, clinically significant arrhythmias",other,f,0,"{""text"": ""Has a history of, or current, clinically significant arrhythmias"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.347702
CIN-102-123,exclusion,"Has evidence or history of clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease",laboratory,f,0,"{""text"": ""Has evidence or history of clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.580323
CIN-102-123,exclusion,Has clinically significant abdominal surgical conditions or cancer that might interfere with the study drug,other,f,0,"{""text"": ""Has clinically significant abdominal surgical conditions or cancer that might interfere with the study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.492408
CIN-102-123,exclusion,"Any condition that, in the Investigator’s opinion, might significantly interfere with the absorption, distribution, metabolism, or excretion of the study drug",other,f,0,"{""text"": ""Any condition that, in the Investigator’s opinion, might significantly interfere with the absorption, distribution, metabolism, or excretion of the study drug"", ""field"": ""unparsed""}",2025-04-05 14:44:46.246757,2025-07-28 19:35:36.421299
CIN-103-121,inclusion,Are adult male and female subjects ≥18 years of age,demographic,t,0,"{""text"": ""Are adult male and female subjects ≥18 years of age"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:26.170235
CIN-103-121,inclusion,"Have a body mass index between 18 and 45 kg/m2, inclusive at Screening",other,t,0,"{""text"": ""Have a body mass index between 18 and 45 kg/m2, inclusive at Screening"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,"Meet Rome IV Criteria for IBS-D by subject self-report of recurrent abdominal pain that is associated with ≥2 of the following over the last ≥6 months, with frequency of at least 1 day per week over the last 3 months (on average) before enrollment: Related to defecation; Associated with a change in frequency of stool; and/or Associated with a change in form (appearance of stool)",demographic,t,0,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:26.170235
CIN-103-121,inclusion,"Based on Investigator interview of subject’s symptoms over the last 3 months, have ≥25% of bowel movements (BMs) with Bristol Stool Scale (BSS) Type 6 or 7 (loose or watery stools) and <25% of BMs with BSS Type 1 or 2 (lumpy or hard stools) per the Rome IV Criteria for IBS-D",other,t,0,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,"In the opinion of the Investigator, are on a stable diet for ≥4 weeks prior to Screening and are not planning to change lifestyle, exercise, and/or diet that may impact symptoms of IBS-D during study participation",other,t,0,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,Have a fecal calprotectin ≤ 100 mcg/g at the Screening Visit or Visit 2,other,t,0,"{""text"": ""Have a fecal calprotectin ≤ 100 mcg/g at the Screening Visit or Visit 2"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,Have a serum tTG-IgA (tissue transglutaminase immunoglobulin A) ≤4.99 FLU at the Screening Visit,other,t,0,"{""text"": ""Have a serum tTG-IgA (tissue transglutaminase immunoglobulin A) ≤4.99 FLU at the Screening Visit"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,"Have undergone a colonoscopy examination within the designated time interval prior to randomization, if they meet any of the following criteria: Average risk, based on US Preventive Services Task Force Recommendation Statement for screening of colorectal cancer, with age ≥45 years (colonoscopy within 10 years or negative test results on Cologuard within 3 years); Personal history of completely removed adenomatous colorectal polyps (colonoscopy within 5 years for polyps >1 cm, within 10 years for polyps <1 cm); History of colorectal cancer or adenomatous polyps in a first-degree relative before age 60 (colonoscopy within 5 years); or History of colorectal cancer or adenomatous polyps in ≥2 first-degree relatives at any age, or family history of hereditary colorectal cancer or polyposis (colonoscopy within 5 years)",demographic,t,0,"{""text"": ""Have undergone a colonoscopy examination within the designated time interval prior to randomization, if they meet any of the following criteria: Average risk, based on US Preventive Services Task Force Recommendation Statement for screening of colorectal cancer, with age ≥45 years (colonoscopy within 10 years or negative test results on Cologuard within 3 years); Personal history of completely removed adenomatous colorectal polyps (colonoscopy within 5 years for polyps >1 cm, within 10 years for polyps <1 cm); History of colorectal cancer or adenomatous polyps in a first-degree relative before age 60 (colonoscopy within 5 years); or History of colorectal cancer or adenomatous polyps in ≥2 first-degree relatives at any age, or family history of hereditary colorectal cancer or polyposis (colonoscopy within 5 years)"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:26.170235
CIN-103-121,inclusion,"Female subjects of childbearing potential must have a negative pregnancy test result at the Screening Visit, Visit 2, and Visit 3 (prior to randomization and the first dose of study drug); must not be pregnant, lactating, or planning a pregnancy during the study; and agree to use 2 medically accepted, effective methods of birth control from Day -14 until 6 months after the last dose of study drug",laboratory,t,0,"{""text"": ""Female subjects of childbearing potential must have a negative pregnancy test result at the Screening Visit, Visit 2, and Visit 3 (prior to randomization and the first dose of study drug); must not be pregnant, lactating, or planning a pregnancy during the study; and agree to use 2 medically accepted, effective methods of birth control from Day -14 until 6 months after the last dose of study drug"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,"Female subjects of non-childbearing potential with male partners must either be surgically sterile (full hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit), or postmenopausal (defined as no menses for 12 months without an alternative medical cause and should have a high follicle-stimulating hormone level in the postmenopausal range at Screening, based on the central laboratory’s range)",laboratory,t,0,"{""text"": ""Female subjects of non-childbearing potential with male partners must either be surgically sterile (full hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit), or postmenopausal (defined as no menses for 12 months without an alternative medical cause and should have a high follicle-stimulating hormone level in the postmenopausal range at Screening, based on the central laboratory’s range)"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,"Male subjects with female partners of childbearing potential must be willing and agree to use a single effective method of birth control (eg, condom with spermicide) during their participation in the study and for 90 days after the last dose of study drug",other,t,0,"{""text"": ""Male subjects with female partners of childbearing potential must be willing and agree to use a single effective method of birth control (eg, condom with spermicide) during their participation in the study and for 90 days after the last dose of study drug"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,Must agree to abstain from sperm donation through 90 days after the last dose of study drug or egg donation through 6 months after the last dose of study drug,other,t,0,"{""text"": ""Must agree to abstain from sperm donation through 90 days after the last dose of study drug or egg donation through 6 months after the last dose of study drug"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,inclusion,"Can understand and comply with all study visits, procedures, restrictions, discontinuation of medications, including those to treat IBS-D (as specified in the Protocol) and provide written informed consent according to institutional and regulatory guidelines",other,t,0,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,exclusion,"Have a diagnosis or suspected diagnosis of non-diarrhea predominant IBS (eg, IBS with a subtype of constipation, IBS with mixed or alternating bowel habits, un-subtyped IBS) or functional constipation by the Rome IV Criteria",medical,t,0,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:26.170235
CIN-103-121,exclusion,"Non-infectious chronic lower gastrointestinal conditions including a history of or current inflammatory bowel disease (ie, Crohn’s disease, ulcerative colitis, indeterminate colitis), recurrent diverticulitis, microscopic colitis, lymphocytic colitis, celiac disease, non-celiac gluten sensitivity and non-compliant on a gluten-free diet, untreated lactose intolerance, carcinoid syndrome, Lynch syndrome, or familial polyposis, intestinal obstruction, stricture, toxic megacolon, solitary rectal ulcer syndrome, GI perforation, intra-abdominal or pelvic adhesions, ischemic colitis, radiation proctitis, chronic enteritis, non-infectious colitis, or impaired intestinal circulation (eg, aortoiliac disease)",laboratory,t,0,"{""text"": ""Non-infectious chronic lower gastrointestinal conditions including a history of or current inflammatory bowel disease (ie, Crohn’s disease, ulcerative colitis, indeterminate colitis), recurrent diverticulitis, microscopic colitis, lymphocytic colitis, celiac disease, non-celiac gluten sensitivity and non-compliant on a gluten-free diet, untreated lactose intolerance, carcinoid syndrome, Lynch syndrome, or familial polyposis, intestinal obstruction, stricture, toxic megacolon, solitary rectal ulcer syndrome, GI perforation, intra-abdominal or pelvic adhesions, ischemic colitis, radiation proctitis, chronic enteritis, non-infectious colitis, or impaired intestinal circulation (eg, aortoiliac disease)"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,exclusion,"Infectious lower gastrointestinal conditions requiring antibiotics or microbiome therapy; any microbiologically documented acute lower gastrointestinal colitis or enteritis requiring antibiotic treatment including successfully treated Clostridioides difficile colitis within 3 months prior to Screening, or a history of recurrent C. difficile colitis at any time in the past",laboratory,t,0,"{""text"": ""Infectious lower gastrointestinal conditions requiring antibiotics or microbiome therapy; any microbiologically documented acute lower gastrointestinal colitis or enteritis requiring antibiotic treatment including successfully treated Clostridioides difficile colitis within 3 months prior to Screening, or a history of recurrent C. difficile colitis at any time in the past"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,exclusion,Have a known family history of inflammatory bowel disease in at least 1 first-degree relative,other,t,0,"{""text"": ""Have a known family history of inflammatory bowel disease in at least 1 first-degree relative"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,exclusion,"Have a known history of a pelvic floor disorder associated with constipation (unless successful treatment has been documented by a normal balloon expulsion test or anorectal manometry), refractory constipation not responsive to standard medical therapy, fecal impaction that required hospitalization, cathartic colon, and/or active proctological condition",laboratory,t,0,"{""text"": ""Have a known history of a pelvic floor disorder associated with constipation (unless successful treatment has been documented by a normal balloon expulsion test or anorectal manometry), refractory constipation not responsive to standard medical therapy, fecal impaction that required hospitalization, cathartic colon, and/or active proctological condition"", ""field"": ""unparsed""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
CIN-103-121,exclusion,"Have a history of or current non-IBS chronic condition(s) with ongoing symptoms associated with abdominal pain or GI discomfort (eg, gastroparesis, functional dyspepsia, uncontrolled)",other,t,0,"{""field"": ""diagnosis"", ""value"": ""IBS""}",2025-04-01 20:57:49.084975,2025-04-11 13:31:10.984483
D8460C0004,inclusion,"BMI ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 plus a documented history of or currently being treated for at least one of the following co-morbidities: hypertension, dyslipidaemia or obstructive sleep apnoea",biometric,t,0,"{""field"": ""diagnosis"", ""value"": ""hypertension""}",2025-04-01 18:41:12.205758,2025-04-11 13:31:10.984483
K304-P001,inclusion,"Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.",demographic,t,0,"{""text"": ""Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:26.170235
K304-P001,inclusion,"Patient has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated.",other,t,0,"{""text"": ""Patient has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483
K304-P001,inclusion,Patient has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).,other,t,0,"{""text"": ""Patient has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1)."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483
K304-P001,inclusion,Meet the following requirements: Is a male OR Is a female who is of non-childbearing potential OR Is a female of reproductive potential and agrees to remain abstinent from heterosexual activity or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit.,demographic,t,0,"{""text"": ""Meet the following requirements: Is a male OR Is a female who is of non-childbearing potential OR Is a female of reproductive potential and agrees to remain abstinent from heterosexual activity or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:26.170235
K304-P001,inclusion,Patient voluntarily agrees to participate in the study by giving written informed consent.,other,t,0,"{""text"": ""Patient voluntarily agrees to participate in the study by giving written informed consent."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483
K304-P001,inclusion,"Patient is able to read, understand and complete the study questionnaires and diary.",other,t,0,"{""text"": ""Patient is able to read, understand and complete the study questionnaires and diary."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483
K304-P001,inclusion,"Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.",other,t,0,"{""text"": ""Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483
K304-P001,inclusion,"Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.",other,t,0,"{""text"": ""Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483
K304-P001,exclusion,"Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study.",other,t,0,"{""text"": ""Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study."", ""field"": ""unparsed""}",2025-04-05 14:50:56.540928,2025-04-11 13:31:10.984483
ORA-D-013-3,inclusion,1. Male and female subjects aged ≥ 50 years.,demographics,t,0,,2025-07-28 19:38:39.656681,2025-07-28 19:38:39.656681
ORA-D-013-3,inclusion,2. Established diagnosis of T2DM for at least 6 months prior to Screening AND an A1C ≥ 7.2% but ≤ 10.0% at Screening.,laboratory,t,0,,2025-07-28 19:38:39.706686,2025-07-28 19:38:39.706686
ORA-D-013-3,inclusion,"3. On a stable dose of at least one and up to three of the following glucose-lowering agents: Metformin, sulfonylurea, DPP-4 inhibitor, SGLT-2 inhibitor, thiazolidinedione, insulin secretagogue, oral or injected GLP-1 receptor agonists, glucosidase inhibitor, or pramlintide (injected insulin is excluded) for a minimum of 3 months prior to Screening.",demographics,t,0,,2025-07-28 19:38:39.746513,2025-07-28 19:38:39.746513
ORA-D-013-3,inclusion,"4. Body mass index (BMI) of ≤ 28 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening.",disease_specific,t,0,,2025-07-28 19:38:39.779808,2025-07-28 19:38:39.779808
ORA-D-013-3,inclusion,5. Renal function – eGFR ≥ 30 ml/min.,laboratory,t,0,,2025-07-28 19:38:39.815643,2025-07-28 19:38:39.815643
ORA-D-013-3,inclusion,6. Females of childbearing potential must:,demographics,t,0,,2025-07-28 19:38:39.856198,2025-07-28 19:38:39.856198
ORA-D-013-3,inclusion,a. Have a negative serum pregnancy test result at Screening.,laboratory,t,0,,2025-07-28 19:38:39.892492,2025-07-28 19:38:39.892492
ORA-D-013-3,inclusion,"b. Agree to avoid becoming pregnant while receiving IP for at least 30 days prior to IP administration, during the entire study, and for 30 days following their last dose of IP.",laboratory,t,0,,2025-07-28 19:38:39.929082,2025-07-28 19:38:39.929082
ORA-D-013-3,inclusion,"c. Agree to use an acceptable method of contraception at least 30 days prior to IP administration, during the entire study, and for 30 days following their last dose of IP. Acceptable methods of contraception are hormonal contraception (contraceptive pill or injection) PLUS an additional barrier method of contraception such as a diaphragm, condom, sponge, or spermicide.",demographics,t,0,,2025-07-28 19:38:39.976944,2025-07-28 19:38:39.976944
ORA-D-013-3,inclusion,"d. In the absence of hormonal contraception, double-barrier methods must be used which include a combination of any two of the following: diaphragm, condom, copper intrauterine device, sponge, or spermicide, and must be used for at least 30 days prior to administration of IP, during the entire study, and for 30 days following their last dose of IP.",demographics,t,0,,2025-07-28 19:38:40.018806,2025-07-28 19:38:40.018806
ORA-D-013-3,inclusion,"e. Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the subject’s preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.",demographics,t,0,,2025-07-28 19:38:40.053469,2025-07-28 19:38:40.053469
ORA-D-013-3,inclusion,f. Females who are not of childbearing potential are defined as:,demographics,t,0,,2025-07-28 19:38:40.087227,2025-07-28 19:38:40.087227
ORA-D-013-3,inclusion,i. Postmenopausal (defined as at least 12 months with no menses in women ≥ 45 years of age); OR,demographics,t,0,,2025-07-28 19:38:40.125281,2025-07-28 19:38:40.125281
ORA-D-013-3,inclusion,"ii. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR",laboratory,t,0,,2025-07-28 19:38:40.158955,2025-07-28 19:38:40.158955
ORA-D-013-3,inclusion,iii. Have a congenital or acquired condition that prevents childbearing.,disease_specific,t,0,,2025-07-28 19:38:40.19239,2025-07-28 19:38:40.19239
ORA-D-013-3,exclusion,1. Type 1 diabetes by history.,disease_specific,t,0,,2025-07-28 19:38:40.230928,2025-07-28 19:38:40.230928
ORA-D-013-3,exclusion,"2. Diabetes attributable to other secondary causes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).",disease_specific,t,0,,2025-07-28 19:38:40.272318,2025-07-28 19:38:40.272318
ORA-D-013-3,exclusion,3. Treatment involving injected insulin within 3 months prior to Visit 1.,medical_history,t,0,,2025-07-28 19:38:40.309383,2025-07-28 19:38:40.309383
ORA-D-013-3,exclusion,4. A history of > 2 episodes of severe hypoglycemia within 6 months prior to Screening.,disease_specific,t,0,,2025-07-28 19:38:40.351507,2025-07-28 19:38:40.351507
ORA-D-013-3,exclusion,5. A history of hypoglycemic unawareness.,medical_history,t,0,,2025-07-28 19:38:40.385079,2025-07-28 19:38:40.385079
ORA-D-013-3,exclusion,"6. A history of unstable angina or myocardial infarction within 6 months prior to Screening, New York Heart Association (NYHA) Grade 3 or 4 congestive heart failure (CHF), valvular heart disease, ventricular cardiac arrhythmia requiring treatment, pulmonary hypertension, cardiac surgery, coronary angioplasty, stroke, or transient ischemic attack (TIA) within 6 months prior to Screening.",laboratory,t,0,,2025-07-28 19:38:40.424705,2025-07-28 19:38:40.424705
ORA-D-013-3,exclusion,7. A history of uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg. A single repeat measurement will be permitted.,laboratory,t,0,,2025-07-28 19:38:40.458257,2025-07-28 19:38:40.458257
ORA-D-013-3,exclusion,8. Renal dysfunction: eGFR < 30 mL/min.,laboratory,t,0,,2025-07-28 19:38:40.497043,2025-07-28 19:38:40.497043
ORA-D-013-3,exclusion,9. A history of or active proliferative retinopathy requiring treatment.,medical_history,t,0,,2025-07-28 19:38:40.534626,2025-07-28 19:38:40.534626
ORA-D-013-3,exclusion,"10. Psychiatric disorders that, per Investigator judgment, may have impact on the safety of the subject or interfere with subject’s participation or compliance in the study.",disease_specific,t,0,,2025-07-28 19:38:40.568026,2025-07-28 19:38:40.568026
ORA-D-013-3,exclusion,11. Laboratory abnormalities at Screening including:,laboratory,t,0,,2025-07-28 19:38:40.606734,2025-07-28 19:38:40.606734
ORA-D-013-3,exclusion,a. Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or >1.5X the upper limit of normal; a single repeat test is allowable.,laboratory,t,0,,2025-07-28 19:38:40.642784,2025-07-28 19:38:40.642784
ORA-D-013-3,exclusion,"b. Elevated liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)) > 3X the upper limit of normal; a single repeat test is allowable.",laboratory,t,0,,2025-07-28 19:38:40.685664,2025-07-28 19:38:40.685664
ORA-D-013-3,exclusion,c. Very elevated fasting triglyceride levels (> 600 mg/dL); a single repeat test is allowable.,laboratory,t,0,,2025-07-28 19:38:40.730193,2025-07-28 19:38:40.730193
ORA-D-013-3,exclusion,d. Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration.,medications,t,0,,2025-07-28 19:38:40.769582,2025-07-28 19:38:40.769582
ORA-D-013-3,exclusion,"12. Positive history of active liver disease (other than non-alcoholic hepatic steatosis), primary biliary cirrhosis, or active symptomatic gallbladder disease.",laboratory,t,0,,2025-07-28 19:38:40.822137,2025-07-28 19:38:40.822137
ORA-D-013-3,exclusion,"13. Positive results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus ribonucleic acid (RNA).",general,t,0,,2025-07-28 19:38:40.86443,2025-07-28 19:38:40.86443
ORA-D-013-3,exclusion,14. Patient has active or history of neoplastic disease (except for adequately treated non-invasive basal cell and/or squamous cell carcinoma or carcinoma in situ of the cervix) within the past 5 years prior to baseline.,laboratory,t,0,,2025-07-28 19:38:40.908447,2025-07-28 19:38:40.908447
ORA-D-013-3,exclusion,15. Use of the following medications:,medications,t,0,,2025-07-28 19:38:40.944506,2025-07-28 19:38:40.944506
ORA-D-013-3,exclusion,a. History of use of any injectable insulin (greater than 7 days) within 6 months prior to Screening.,medical_history,t,0,,2025-07-28 19:38:40.981189,2025-07-28 19:38:40.981189
ORA-D-013-3,exclusion,b. Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.,laboratory,t,0,,2025-07-28 19:38:41.020404,2025-07-28 19:38:41.020404
ORA-D-013-3,exclusion,"c. Use of oral, intravenous, or intramuscular steroids for one month prior to enrollment. Intra-articular and/or topical corticosteroids are not considered systemic.",medical_history,t,0,,2025-07-28 19:38:41.061288,2025-07-28 19:38:41.061288
ORA-D-013-3,exclusion,"d. Concurrent use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and immunosuppressive or immunomodulating agents. Inhaled nasal steroids are permissible.",demographics,t,0,,2025-07-28 19:38:41.096105,2025-07-28 19:38:41.096105
ORA-D-013-3,exclusion,16. Known allergy to soy.,safety,t,0,,2025-07-28 19:38:41.13665,2025-07-28 19:38:41.13665
ORA-D-013-3,exclusion,"17. Involvement in a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide) within 3 months prior to Screening.",medical_history,t,0,,2025-07-28 19:38:41.171427,2025-07-28 19:38:41.171427
ORA-D-013-3,exclusion,18. Prior bariatric surgery.,medical_history,t,0,,2025-07-28 19:38:41.206987,2025-07-28 19:38:41.206987
ORA-D-013-3,exclusion,19. Subject is pregnant or breast-feeding.,laboratory,t,0,,2025-07-28 19:38:41.242758,2025-07-28 19:38:41.242758
ORA-D-013-3,exclusion,20. Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by > 3 drinks per day or > 14 drinks per week or binge drinking) at Screening. Occasional intermittent use of cannabinoid products will be allowed provided that no cannabinoid products have been used during the 1 week prior to each visit.,disease_specific,t,0,,2025-07-28 19:38:41.277434,2025-07-28 19:38:41.277434
ORA-D-013-3,exclusion,21. Weight loss preparations either approved and marketed or used in OTC preparations except for GLP-1 used in the treatment of underlying diabetes.,laboratory,t,0,,2025-07-28 19:38:41.315216,2025-07-28 19:38:41.315216
ORA-D-013-3,exclusion,22. Any condition or other factor (at the Investigator’s discretion) that is deemed unsuitable for subject enrollment into the study.,disease_specific,t,0,,2025-07-28 19:38:41.365791,2025-07-28 19:38:41.365791
VBE00001,inclusion,I01: Aged 18 to 45 years on the day of the first study intervention administration a,demographics,t,0,,2025-07-24 22:04:50.071112,2025-07-24 22:04:50.071112
VBE00001,inclusion,"I02: Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests as judged by the investigator",laboratory,f,0,,2025-07-24 22:04:50.111165,2025-07-25 16:15:03.466246
VBE00001,inclusion,"I03: Clinical diagnosis of moderate or severe facial acne vulgaris with: • IGA score of Moderate or Severe (grade 3 or grade 4 on the 5-grade IGA scale) AND • ≥ 25 non-inflammatory lesions (ie, open and closed comedones) AND • ≥ 20 inflammatory lesions (ie, papules and pustules) AND • ≤ 2 nodulocystic lesions (ie, nodules and cysts)",disease_specific,f,0,,2025-07-24 22:04:50.147237,2025-07-25 16:15:06.522075
VBE00001,inclusion,"I04: A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions appliesb: • Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile OR • Is of childbearing potential and agrees to use an effective contraceptive methodc or abstinence from at least 4 weeks prior to the first study intervention administration until at least 4 weeks after the last study intervention administration A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) before the first study intervention administration",demographics,f,0,,2025-07-24 22:04:50.184869,2025-07-25 16:15:08.861956
VBE00001,inclusion,I05: Informed consent form has been signed and dateda,study_procedures,f,0,,2025-07-24 22:04:50.222203,2025-07-25 16:15:10.83772
VBE00001,inclusion,I06: Able to attend all scheduled visits and to comply with all study procedures,study_procedures,f,0,,2025-07-24 22:04:50.258419,2025-07-25 16:15:12.719822
VBE00001,inclusion,I07: Refrain from use of any other acne treatments for the duration of the study (pre-specified non-medicated cleansers and sunscreen will be allowedb),disease_specific,t,0,,2025-07-24 22:04:50.296129,2025-07-24 22:04:50.296129
VBE00001,exclusion,"E01: Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the first study intervention administration; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)",laboratory,f,0,,2025-07-24 22:04:50.331957,2025-07-25 16:15:34.46955
VBE00001,exclusion,"E02: Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol [PEG], polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substancesc; any allergic reaction (eg, anaphylaxis) after administration of mRNA coronavirus disease 2019 (COVID-19) vaccine",disease_specific,t,0,,2025-07-24 22:04:50.37548,2025-07-24 22:04:50.37548
VBE00001,exclusion,E03: Previous history of myocarditis and/or pericarditis and/or myopericarditis,medical_history,t,0,,2025-07-24 22:04:50.411584,2025-07-24 22:04:50.411584
VBE00001,exclusion,"E04: Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion",demographics,f,0,,2025-07-24 22:04:50.454407,2025-07-25 16:15:38.73785
VBE00001,exclusion,"E05: Thrombocytopenia, bleeding disorder, or receipt of anticoagulants contraindicating intramuscular injection based on investigator’s judgement",laboratory,f,0,,2025-07-24 22:04:50.492513,2025-07-25 16:15:39.940987
VBE00001,exclusion,"E06: Active nodulocystic acne, acne conglobate, acne fulminans, secondary acne (eg, chloracne, drug-induced acne) or other forms of acne (eg, acne mechanica)",disease_specific,f,0,,2025-07-24 22:04:50.533365,2025-07-25 16:15:42.723176
VBE00001,exclusion,"E07: Skin pathology or condition that, in the investigator’s opinion, could interfere with the evaluation of the study intervention or requires use of interfering topical, systemic, or surgical therapya",disease_specific,f,0,,2025-07-24 22:04:50.569354,2025-07-25 16:15:48.896278
VBE00001,exclusion,"E08: Excessive facial hair, facial tattoos, facial skin disorders, skin reactions that may interfere with the study assessments in the investigator’s opinion (including – but not limited to – actinic keratosis, eczema, psoriasis, seborrheic dermatitis, rosacea, acute or recent sunburn) or skin infection",disease_specific,f,0,,2025-07-24 22:04:50.612172,2025-07-25 16:15:53.926505
VBE00001,exclusion,"E09: Alcohol, prescription drug, or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion",laboratory,f,0,,2025-07-24 22:04:50.6462,2025-07-25 16:15:55.621465
VBE00001,exclusion,E10: Start or switch of hormonal contraceptive use within 12 weeks prior to the first study intervention administration or plans to initiate or switch hormonal contraceptive products during the study periodb,demographics,t,0,,2025-07-24 22:04:50.681562,2025-07-24 22:04:50.681562
VBE00001,exclusion,E11: Previous use of oral isotretinoin,medical_history,f,0,,2025-07-24 22:04:50.715987,2025-07-25 16:16:00.491716
VBE00001,exclusion,E12: Use of any acne-affecting treatment without an appropriate washout period. Participants receiving prohibited medications/therapies at Screening Visit will have to observe a washout period of 2 weeks to 24 weeks before enrolment (as specified in the table below) to preserve eligibility in the study.,disease_specific,f,0,,2025-07-24 22:04:50.75133,2025-07-25 16:16:03.432624
VBE00001,exclusion,E13: Receipt of any vaccine (other than the study vaccine) in the 4 weeks preceding any study intervention administration or planned receipt of any vaccine (other than the study vaccine) in the 4 weeks following any study intervention administration,laboratory,t,0,,2025-07-24 22:04:50.787221,2025-07-24 22:04:50.787221
VBE00001,exclusion,E14: Receipt of any mRNA vaccine in the 60 days preceding any study intervention administration or planned receipt of any mRNA vaccine in the 60 days following any study intervention administration,laboratory,f,0,,2025-07-24 22:04:50.824435,2025-07-25 16:16:11.712794
VBE00001,exclusion,E15: Previous vaccination against C. acnes with an investigational vaccine,disease_specific,f,0,,2025-07-24 22:04:50.86163,2025-07-25 16:16:19.446528
VBE00001,exclusion,"E16: Receipt of immune globulins, blood or blood-derived products in the past 3 months",laboratory,f,0,,2025-07-24 22:04:50.899743,2025-07-25 16:16:22.509308
VBE00001,exclusion,"E17: Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus",general,f,0,,2025-07-24 22:04:50.95186,2025-07-25 16:16:23.772672
VBE00001,exclusion,"E18: Participation at the time of study enrollment (or in the 4 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure",medications,f,0,,2025-07-24 22:04:50.993799,2025-07-25 16:16:26.235845
VBE00001,exclusion,E19: Planned participation in strenuous or endurance exercise up to D08 after any study intervention administrationa,medications,f,0,,2025-07-24 22:04:51.031512,2025-07-25 16:16:28.382396
VBE00001,exclusion,"E20: Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily",general,f,0,,2025-07-24 22:04:51.070942,2025-07-25 16:16:34.792626
VBE00001,exclusion,"E21: Identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study",laboratory,f,0,,2025-07-24 22:04:51.107454,2025-07-25 16:16:35.862099
VBE00001,exclusion,E22: Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided,disease_specific,f,0,,2025-07-24 22:04:51.147444,2025-07-25 16:18:29.23077
VBE00001,exclusion,"E23: Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.",demographics,f,0,,2025-07-24 22:04:51.182615,2025-07-25 16:18:26.975738
VBE00001,exclusion,"E24: Participants with a screening electrocardiogram that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results",safety,f,0,,2025-07-24 22:04:51.222621,2025-07-25 16:18:31.163224
VBE00001,exclusion,E25: Any screening laboratory parameter with laboratory abnormalities that are Grade 2 or above or deemed clinically significant in the opinion of the investigator,laboratory,f,0,,2025-07-24 22:04:51.258857,2025-07-25 16:18:32.217357
